Sutro Biopharma, Inc.
Records under this name other than the patents Sutro Biopharma, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 45 patents it holds.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,827,684 | HUMAN INTERLEUKIN-2 CONJUGATES BIASED FOR THE INTERLEUKIN-2 RECEPTOR BETA GAMMAc DIMER AND CONJUGATED TO A NONPEPTIDIC, WATER-SOLUBLE POLYMER Formerly held In force · High confidence | In force | High confidence | |
| US 9,988,619 | Non-natural amino acid tRNA synthetases for pyridyl tetrazine Lapsed on the fee record Ended Jun 5, 2026 · USPTO record | Lapsed on the fee record | Ended Jun 5, 2026 | USPTO record |
| US 9,896,685 | Use of LAMBDA-GAM protein in ribosomal display technology Lapsed on the fee record Ended Feb 20, 2026 · USPTO record | Lapsed on the fee record | Ended Feb 20, 2026 | USPTO record |
| US 9,840,493 | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use Lapsed on the fee record Ended Dec 12, 2025 · USPTO record | Lapsed on the fee record | Ended Dec 12, 2025 | USPTO record |
| US 11,098,131 | Anti-EpCAM antibodies, compositions comprising anti-EpCAM antibodies and methods of making and using anti-EpCAM antibodies Lapsed on the fee record Ended Aug 24, 2025 · USPTO record | Lapsed on the fee record | Ended Aug 24, 2025 | USPTO record |
| US 11,014,983 | Anti-Tim-3 antibodies, compositions comprising anti-Tim-3 antibodies and methods of making and using anti-Tim-3 antibodies Lapsed on the fee record Ended May 25, 2025 · USPTO record | Lapsed on the fee record | Ended May 25, 2025 | USPTO record |
| US 10,975,150 | Anti-CD74 antibodies, compositions comprising anti-CD74 antibodies and methods of using anti-CD74 antibodies Lapsed on the fee record Ended Apr 13, 2025 · USPTO record | Lapsed on the fee record | Ended Apr 13, 2025 | USPTO record |
| US 10,822,414 | Anti-PD-1 antibodies, compositions comprising anti-PD-1 antibodies and methods of using anti-PD-1 antibodies Lapsed on the fee record Ended Nov 3, 2024 · USPTO record | Lapsed on the fee record | Ended Nov 3, 2024 | USPTO record |
| US 10,731,148 | Use of lambda-gam protein in ribosomal display technology Lapsed on the fee record Ended Aug 4, 2024 · USPTO record | Lapsed on the fee record | Ended Aug 4, 2024 | USPTO record |
| US 10,442,789 | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use Lapsed on the fee record Ended Oct 15, 2023 · USPTO record | Lapsed on the fee record | Ended Oct 15, 2023 | USPTO record |